Treatment of High-Titer Phospholipase A2 Receptor Autoantibody Membranous Nephropathy with Rituximab (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #PUB170; "Although Obinutuzumab was considered due to the high titer, the patient was ultimately treated with Rituximab (1 g x 2 doses, 14 days apart) along with losartan, spironolactone, cyclosporine, and apixaban. Second, B-cell depletion is correlated with a reduction in PLA2R burden, highlighting its effectiveness as a viable option to monitor therapeutic efficacy. Third, the reduction in PLA2R antibody precedes clinical improvement."
Addiction (Opioid and Alcohol) • Cardiovascular • Diabetes • Glomerulonephritis • Hypertension • Metabolic Disorders • Nephrology • Nicotine Addiction • Renal Disease • Type 1 Diabetes Mellitus
|
|
William Michael Haas; Roderick J. Tan; Mohan Ramkumar
|